French firm Defymed has developed a new insulin delivery device ExOlin to facilitate better disease management for both type 1 and type 2 diabetes patients.
ExOlin consists of a biocompatible membrane that is non-biodegradable and permeable to insulin.
The device is designed as an abdominal implant and allows delivery of insulin to a physiological site when injected through the skin, in contrast to other tools such as pens and external pumps involving subcutaneous delivery.
